Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Infections 3Neutropenia 2Soft Tissue Infections 1Lymphoma, Follicular 1Hot Flashes 1Hematologic Neoplasms 1Fournier Gangrene 1Fever 1Fasciitis, Necrotizing 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × Daptomycin × Clear all
NCT00261807 2022-01-27

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

University of Maryland, Baltimore

Phase NA Completed
25 enrolled 7 charts
Lymphoid

Infections, Lymphoma, Follicular, Soft Tissue Infections, Fournier Gangrene, Fasciitis, Necrotizing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡